Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 7.35 -0.68% -0.05
TGTX closed down 0.68 percent on Wednesday, November 22, 2017, on 1.63 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical TGTX trend table...

Date Alert Name Type % Chg
Nov 22 NR7 Range Contraction 0.00%
Nov 22 Narrow Range Bar Range Contraction 0.00%
Nov 22 Stochastic Reached Oversold Other 0.00%
Nov 22 Lower Bollinger Band Walk Other 0.00%
Nov 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -11.45%
Nov 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -13.02%
Nov 14 Stochastic Reached Overbought Other -15.03%
Nov 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -15.03%
Nov 13 Death Cross Bearish -10.91%
Nov 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -10.91%

Older signals for TGTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Is TGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.35
52 Week Low 4.1
Average Volume 1,315,544
200-Day Moving Average 10.4448
50-Day Moving Average 9.7073
20-Day Moving Average 7.9845
10-Day Moving Average 8.055
Average True Range 0.5238
ADX 24.84
+DI 15.4
-DI 28.61
Chandelier Exit (Long, 3 ATRs ) 7.3786
Chandelier Exit (Short, 3 ATRs ) 8.8214
Upper Bollinger Band 8.6896
Lower Bollinger Band 7.2794
Percent B (%b) 0.05
BandWidth 17.66172
MACD Line -0.5059
MACD Signal Line -0.5474
MACD Histogram 0.0415
Fundamentals Value
Market Cap 457.98 Million
Num Shares 62.3 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -3.77
Price-to-Sales 3189.49
Price-to-Book 6.24
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.73
Resistance 3 (R3) 7.73 7.62 7.66
Resistance 2 (R2) 7.62 7.52 7.61 7.64
Resistance 1 (R1) 7.48 7.46 7.43 7.48 7.62
Pivot Point 7.37 7.37 7.34 7.36 7.37
Support 1 (S1) 7.23 7.27 7.18 7.23 7.08
Support 2 (S2) 7.12 7.21 7.11 7.06
Support 3 (S3) 6.98 7.12 7.04
Support 4 (S4) 6.98